Enumeral Biomedical Holdings Inc
Enumeral Biomedical — Investor Presentation (October 2016)
27 slides from Enumeral Biomedical's investor presentation, Oct 28, 2016
Slide 1: Enumeral Overview October 2016
Enumeral Overview October 2016 OTCQB: ENUM
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward - looking statements that are based on the company’s current expectations, assumptions, estimates and projections about the company and the pharmaceutical industry . The company makes no representations about the accuracy of such statemen
Slide 3: Company Highlights
Company Highlights • Enumeral is a biotechnology company u tilizing a patented platform to identify novel therapeutics and advance treatments in cancer and other diseases mediated by the immune system • Platform is based on technology exclusively licensed from MIT • Enumeral’s platform has been vali
Slide 4: What's New
What’s New • New Management • Wael Fayad appointed Chairman, President, and CEO • Robert Schaub joined as Interim Head of R&D • New Direction • Focus on partnerships and strategic collaborations • Focus on exploiting platform across therapeutic areas and applications • Focus on discovery to build ow
Slide 5: New Leadership
New Leadership Recently Appointed Wael Fayad • Appointed Chairman, President and CEO in September 2016 • > 20 years of executive and business experience in pharma • 14 years business development track record • Head of business development at Forest Laboratories Inc. • Secured transactions and collab
Slide 6: Strengthened Management Team
Strengthened Management Team 6 Wael Fayad Chairman, President and CEO Bob Schaub, Ph.D. Interim Head of Research and Development • 35 years scientific and executive leadership in pharma and biotech • Expert in translational drug discovery and development of small molecules and biologics • Author of
Slide 7: Point Plan To Create Near Term Value
4 Point Plan To Create Near Term Value • Prioritize strategic collaborations and partnerships to realize the potential of our platform for discovery and development of novel therapeutics • Advance pipeline to near term value inflection points • Secure funding to support plan execution • Position com
Slide 8: Growth Strategy
Growth Strategy • Raise growth capital • Further invest in discovery engine and build a deeper pipeline of therapeutics for high value targets • Close additional transformative deals • Up - list to Nasdaq 8 Focus on Creation of Shareholder Value
Slide 9: Warrant exercise/amendment foundation for potential success
Warrant exercise/amendment foundation for potential success 9 Warrant Exercise and Amendment - Extend runway - Simplify capital s tructure Scenario 1 Institutional round and NASDAQ listing Scenario 2 Interim Financing Deal Flow - Key to value creation Institutional round and NASDAQ listing • Multipl
Slide 10: Planning for Success
Planning for Success • Partner outreach ongoing • Institutional outreach ongoing • Interim financing outreach ongoing • R&D plan in place to advance pipeline to near term value inflection 10 x Management experience x Relationships x Deal making acumen Ingredients for Success High Energy and Motivate
Slide 11: Proprietary Platform Based on Technology Exclusively Licensed from MIT
Proprietary Platform Based on Technology Exclusively Licensed from MIT 11 84,672 50µm micro wells • Broadly enabling proprietary platform for characterization of single cells from healthy or diseased tissue – Isolation – Identification – Characterization Measures key parameters of response of indivi
Slide 12: Tissue Biopsy Approach Drives Translational Research
Tissue Biopsy Approach Drives Translational Research 12 function phenotype genomics Integrated single cell functional profiling Biopsy Proprietary translational biology platform that uses tissue biopsies After Tsioris et al 2015 Approach Enables Our Scientists to Validate, Screen and Select Therapeu
Slide 13: Strategic Focus: Drive Value and Build Pipeline
Strategic Focus: Drive Value and Build Pipeline 13 Solid Foundation for Future Success Discovery • Enumeral’s platform has competitive advantage in discovery and development phases o Exploit full range of potential collaborations to fund business and validate science o Focus on discovery to build ow
Slide 14: Validation from Respected Partners
Validation from Respected Partners* • Pieris Pharmaceuticals – Non - exclusive license agreement • MD Anderson Cancer Center – Co - development agreement • National Cancer Institute – Initially deployed at MGH/ Ragon – Now deployed at Wolchok Lab at Memorial Sloan Kettering • Merck – Research study
Slide 15: Pipeline with Multiple Opportunities
Pipeline with Multiple Opportunities 15 PD - 1 Antibody* ENUM 244C8 PD - 1 Antibody ENUM 388D4 TIM - 3 Antibody CD39 Lead generation Screening Optimization / Differentiation Pre - Clinical Clinical IND Enabling IND Enabling Ready IND Other targets *See Appendix for additional details
Slide 16: Platform with Multiple Applications
Platform with Multiple Applications • Characterization of patient derived samples to identify – New targets – Differentiation of therapeutic agents – Clinical status – Drug development strategies • Identification of novel and diverse antibodies for – Therapeutic intervention – Diagnostics • Characte
Slide 17: Near Term Milestones
Near Term Milestones • Generate robust deal flow – Strategic platform based collaborations – Multiple assets to partner – Two assets of PD - 1, C8 and D4, can be partnered together or separately for different indications – TIM - 3 - can be partnered together or separately for multiple indications •
Slide 18: Significant Value Often Recognized at Pre-Clinical Stage
Significant Value Often Recognized at Pre - Clinical Stage • Discovery and early stage biotechs can have high valuations ‒ CTMX: ~$600M market cap ‒ RGNX: ~$400M market cap • Lucrative deals recently made at the pre - clinical stage ‒ Jounce/Celgene, July 2106 ‒ $225 million upfront + downstream ‒ Z
Slide 19: Key Takeaways
Key Takeaways • Enumeral science works and has potential to create significant value – Deal flow – D ata flow – Institutional capital • Enumeral now has right management and right plan – Experience to execute business plan – Relationships to attract corporate partners and institutional investors • W
Slide 20: Thank You
Thank You Contact: Wael Fayad Chairman, President, and CEO 200 Cambridge Park Drive Cambridge, MA, 02140 wael@enumeral.com O: 617 - 500 - 1613
Slide 21: Appendix
Appendix
Slide 22: Financial Summary
Financial Summary Category Common Shares Outstanding 52,073,481 W arrants Outstanding 24,803,409 * Options Outstanding 6,814,841 ** Cash and Cash Equivalents $1.1M *** 22 OTCQB: ENUM Price: $0.18 Market Cap $9.37M Financial Information & Capitalization (As of June 30, 2016, unless otherwise noted) *
Slide 23: Experienced Board of Directors
Experienced Board of Directors 23 Wael Fayad Chairman, President, and CEO Barry Buckland, Ph.D. Co - Founder; Director; Chairman, Scientific Advisory Board Robert J. Easton Director Allan Rothstein Director Paul J. Sekhri Director Robert L. Van Nostrand Director
Slide 24: PD-1 Status Summary
PD - 1 Status Summary • Generating stable subclone as final stage prior to generation of working and master cell bank • Initiated anti - tumor studies with Crown Bioscience PD - 1 HuGEMM model – Study 1 - Nivolumab dose response to identify no effect and “low” effect dose for study 2 comparison to E
Slide 25: Collaborators Provide External Recognition of Differentiated Approach
Collaborators Provide External Recognition of Differentiated Approach • MERCK : December 2014 collaboration with a leading immuno - oncology pharmaceutical company – Focused on using Enumeral's platform to interrogate the tumor microenvironment in colorectal cancer tissues to identify functional cel
Slide 26: Collaboration with MD Anderson Cancer Center – January 2016
Collaboration with MD Anderson Cancer Center – January 2016 • Goal to Discover and Develop Novel Antibodies Against Specified Immunotherapy Targets – Utilizes Enumeral’s antibody discovery and patient - centric immune profiling platform – Leverages MD Anderson’s preclinical and development expertise
Slide 27: License and Transfer Agreement with Pieris Pharmaceuticals – Spring 2016
License and Transfer Agreement with Pieris Pharmaceuticals – Spring 2016 • Non - exclusive license under specified Enumeral patent rights and know - how to research, develop and market fusion proteins that comprise a moiety derived from Enumeral’s 388D4 anti - PD - 1 antibody linked to one or more P
Enumeral Biomedical Holdings — Investor Presentation (October 2016) on 6ix